Molecular Studies to Identify Mechanisms That Underlie Symptom Improvement in Microbiota Transfer Therapy Patients

Abstract

The purpose of this study is to perform molecular analysis (transcriptomic and metabolomic assays) on samples (whole blood, serum, and stool) derived from 84 adults with autism spectrum disorder (ASD) undergoing microbiota transfer therapy (MTT), and 84 adult controls, from an on-going CDMRP-funded clinical trial (James Adams, PI; Arizona State University) to identify mechanisms that underlie symptom improvement following MTT. Due to the onset of the coronavirus pandemic, recruitment at the ASU site has been severely curtailed since March 2020, and so sample collection and transfer to me has been limited to a portion of the initial 35 ASD sample sets, and 11 control sample sets. Because these samples need to be assayed in batches, although we have begun sample processing, we have not yet begun the molecular assays. We expect to get the assays underway in the Fall of this year (2022) and have requested, and been granted, a no-cost extension to complete the work in 2023.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2022
Accession Number
AD1175581

Entities

People

  • Stephen J. Walker

Organizations

  • Wake Forest University

Tags

DTIC Thesaurus Topics

  • Autism
  • Biomedical Research
  • Blood
  • Chemical Reactions
  • Clinical Trials
  • Data Analysis
  • Department Of Defense
  • Diseases And Disorders
  • Electromagnetic Fields
  • Gene Expression
  • Health
  • Indirect Costs
  • Medical Personnel
  • Microbiomes
  • Pain
  • Polymerase Chain Reaction
  • Therapy

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Microbial Pathology
  • Research Science/Academic Research